Want to see IGC full AI Analyst Report?
IGC Stock Chart & Stats
$0.26
>-$0.01(-0.38%)
At close: 4:00 PM EDT
$0.26
>-$0.01(-0.38%)
Day’s Range― - ―
52-Week Range$0.24 - $0.50
Previous Close$0.27
Volume109.78K
Average Volume (3M)715.71K
Market Cap
$24.92M
Enterprise Value$26.51
Total Cash (Recent Filing)$235.00K
Total Debt (Recent Filing)$933.00K
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Aug 12, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding100,091,320
10 Day Avg. Volume826,885
30 Day Avg. Volume715,709
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.08
Price to Sales (P/S)21.08
P/FCF Ratio-4.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.50Price Target Upside2015.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.09
Revenue Forecast (FY)$1.10M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Debt-free Balance SheetZero reported debt removes fixed interest obligations and preserves financial flexibility. Over the next 2–6 months this durable capital structure lowers short-term liquidity strain, supports negotiating power with lenders, and reduces bankruptcy risk relative to leveraged peers.
Management Alignment Via Debt-to-equity ConversionExecutive conversion of personal advances to equity reduces liabilities without cash outlay, strengthens reported equity, and signals management willingness to absorb dilution. This alignment can improve governance incentives and reduce near-term cash demands, a structural positive for runway.
Maintained $12M Credit FacilityPreserving a $12M banking facility provides a durable liquidity backstop for clinical-stage operations. Access to committed credit reduces the immediacy of equity raises, supports planned R&D expenditures, and gives management time to advance trials or secure strategic funding.
Bears Say
Sharp Revenue ContractionA severe, sustained revenue drop undermines the firm's ability to internally fund R&D and operations. Over months this weak top-line reduces optionality, increases dependency on external capital, and heightens execution risk for progressing clinical programs toward regulatory milestones.
Persistent Negative Operating Cash FlowOngoing negative operating cash flow means the company cannot self-fund operations and will rely on financing. Even with some improvement versus earlier years, persistent cash burn imposes recurring dilution or debt risk, constraining strategic choices and increasing vulnerability to funding cycles.
Material Equity Erosion And Negative ROESubstantial erosion of shareholders' equity reflects cumulative losses and shrinks the capital buffer. This reduces credit capacity, limits flexibility for one-off investments, and signals prolonged unprofitability that could force more dilutive financings over the medium term.
IGC Pharma News
IGC FAQ
What was IGC Pharma’s price range in the past 12 months?
IGC Pharma lowest stock price was $0.23 and its highest was $0.50 in the past 12 months.
What is IGC Pharma’s market cap?
IGC Pharma’s market cap is $24.92M.
When is IGC Pharma’s upcoming earnings report date?
IGC Pharma’s upcoming earnings report date is Aug 12, 2026 which is in 7 days.
How were IGC Pharma’s earnings last quarter?
IGC Pharma released its earnings results on Jun 15, 2026. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is IGC Pharma overvalued?
According to Wall Street analysts IGC Pharma’s price is currently Undervalued.
Does IGC Pharma pay dividends?
IGC Pharma does not currently pay dividends.
What is IGC Pharma’s EPS estimate?
IGC Pharma’s EPS estimate is -0.02.
How many shares outstanding does IGC Pharma have?
IGC Pharma has 100,091,320 shares outstanding.
What happened to IGC Pharma’s price movement after its last earnings report?
IGC Pharma reported an EPS of -$0.02 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of IGC Pharma?
Currently, no hedge funds are holding shares in IGC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IGC Pharma
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
IGC Stock 12 Month Forecast
Average Price Target
$5.50
▲(2015.38% Upside)
Technical Analysis
Ownership Overview
13.06% Insiders
1.37% Mutual Funds
0.05% Other Institutional Investors
83.95% Public Companies and
Individual Investors